Nikolaou Nikolaos et al. demonstrated that AKR1D1 silencing promoted hepatocyte triglyceride accumulation by increasing lipogenesis and fueling hepatocyte inflammation in non-alcoholic fatty liver disease [14, 30]. Here, AKR1D1 is linked to metabolic dysfunction-associated steatotic liver disease.